Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products

LI-2 Protein_564977620_1200.jpg

Related Content

US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards

Apr 21 2018

The New 180 Days? Humira Biosimilar Deals Give Amgen 150-Day Jump On Samsung

Apr 06 2018

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

May 16 2017

Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies

Oct 27 2017

US FDA Recognizes Eight EU Authorities, Triggers Mutual Recognition Provisions

Nov 01 2017

US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry

Jun 01 2017

FDA Biosimilar Education Campaign Will Need To Be Targeted

Sep 17 2015

Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers

Mar 08 2018

Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers

Jun 01 2018

Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability

Jan 18 2017

CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor

Jun 14 2018

Generic Company Disclosure Could Be A 'Speedbump' Against Misuse Of US FDA Access Inquiry List

Jun 08 2018

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Mar 08 2018

Related Companies

AbbVie Inc.

Viatris Inc.

Samsung Bioepis Co., Ltd.

Amgen, Inc.

Additional Topics

United States Biosimilars Review Pathway Regulation Biologics FDA BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window